Cargando…

COVID-19 in early 2021: current status and looking forward

Since the first description of a coronavirus-related pneumonia outbreak in December 2019, the virus SARS-CoV-2 that causes the infection/disease (COVID-19) has evolved into a pandemic, and as of today, >100 million people globally in over 210 countries have been confirmed to have been infected an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengdi, Wang, Zhoufeng, Wang, Guangyu, Lau, Johnson Yiu-Nam, Zhang, Kang, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938042/
https://www.ncbi.nlm.nih.gov/pubmed/33686059
http://dx.doi.org/10.1038/s41392-021-00527-1
_version_ 1783661520551411712
author Wang, Chengdi
Wang, Zhoufeng
Wang, Guangyu
Lau, Johnson Yiu-Nam
Zhang, Kang
Li, Weimin
author_facet Wang, Chengdi
Wang, Zhoufeng
Wang, Guangyu
Lau, Johnson Yiu-Nam
Zhang, Kang
Li, Weimin
author_sort Wang, Chengdi
collection PubMed
description Since the first description of a coronavirus-related pneumonia outbreak in December 2019, the virus SARS-CoV-2 that causes the infection/disease (COVID-19) has evolved into a pandemic, and as of today, >100 million people globally in over 210 countries have been confirmed to have been infected and two million people have died of COVID-19. This brief review summarized what we have hitherto learned in the following areas: epidemiology, virology, and pathogenesis, diagnosis, use of artificial intelligence in assisting diagnosis, treatment, and vaccine development. As there are a number of parallel developments in each of these areas and some of the development and deployment were at unprecedented speed, we also provided some specific dates for certain development and milestones so that the readers can appreciate the timing of some of these critical events. Of note is the fact that there are diagnostics, antiviral drugs, and vaccines developed and approved by a regulatory within 1 year after the virus was discovered. As a number of developments were conducted in parallel, we also provided the specific dates of a number of critical events so that readers can appreciate the evolution of these research data and our understanding. The world is working together to combat this pandemic. This review also highlights the research and development directions in these areas that will evolve rapidly in the near future.
format Online
Article
Text
id pubmed-7938042
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79380422021-03-08 COVID-19 in early 2021: current status and looking forward Wang, Chengdi Wang, Zhoufeng Wang, Guangyu Lau, Johnson Yiu-Nam Zhang, Kang Li, Weimin Signal Transduct Target Ther Review Article Since the first description of a coronavirus-related pneumonia outbreak in December 2019, the virus SARS-CoV-2 that causes the infection/disease (COVID-19) has evolved into a pandemic, and as of today, >100 million people globally in over 210 countries have been confirmed to have been infected and two million people have died of COVID-19. This brief review summarized what we have hitherto learned in the following areas: epidemiology, virology, and pathogenesis, diagnosis, use of artificial intelligence in assisting diagnosis, treatment, and vaccine development. As there are a number of parallel developments in each of these areas and some of the development and deployment were at unprecedented speed, we also provided some specific dates for certain development and milestones so that the readers can appreciate the timing of some of these critical events. Of note is the fact that there are diagnostics, antiviral drugs, and vaccines developed and approved by a regulatory within 1 year after the virus was discovered. As a number of developments were conducted in parallel, we also provided the specific dates of a number of critical events so that readers can appreciate the evolution of these research data and our understanding. The world is working together to combat this pandemic. This review also highlights the research and development directions in these areas that will evolve rapidly in the near future. Nature Publishing Group UK 2021-03-08 /pmc/articles/PMC7938042/ /pubmed/33686059 http://dx.doi.org/10.1038/s41392-021-00527-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Wang, Chengdi
Wang, Zhoufeng
Wang, Guangyu
Lau, Johnson Yiu-Nam
Zhang, Kang
Li, Weimin
COVID-19 in early 2021: current status and looking forward
title COVID-19 in early 2021: current status and looking forward
title_full COVID-19 in early 2021: current status and looking forward
title_fullStr COVID-19 in early 2021: current status and looking forward
title_full_unstemmed COVID-19 in early 2021: current status and looking forward
title_short COVID-19 in early 2021: current status and looking forward
title_sort covid-19 in early 2021: current status and looking forward
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938042/
https://www.ncbi.nlm.nih.gov/pubmed/33686059
http://dx.doi.org/10.1038/s41392-021-00527-1
work_keys_str_mv AT wangchengdi covid19inearly2021currentstatusandlookingforward
AT wangzhoufeng covid19inearly2021currentstatusandlookingforward
AT wangguangyu covid19inearly2021currentstatusandlookingforward
AT laujohnsonyiunam covid19inearly2021currentstatusandlookingforward
AT zhangkang covid19inearly2021currentstatusandlookingforward
AT liweimin covid19inearly2021currentstatusandlookingforward